GT Biopharma Submits IND Application for GTB-5550 TriKE to Treat Solid Tumors.
ByAinvest
Thursday, Jan 15, 2026 9:19 am ET1min read
GTBP--
GT Biopharma has submitted an IND application to the US FDA for GTB-5550 TriKE, a treatment targeting B7-H3 expressing solid tumor cancers. A Phase 1 trial is planned for 2026. The company is also conducting a Phase 1 study of GTB-3650 in myeloid blood cancers, with data expected in the first half of 2026. GT Biopharma has a preliminary cash balance of approximately $7 million, extending its cash runway into Q3 2026.
Stay ahead of the market.
Get curated U.S. market news, insights and key dates delivered to your inbox.
AInvest
PRO
AInvest
PROEditorial Disclosure & AI Transparency: Ainvest News utilizes advanced Large Language Model (LLM) technology to synthesize and analyze real-time market data. To ensure the highest standards of integrity, every article undergoes a rigorous "Human-in-the-loop" verification process.
While AI assists in data processing and initial drafting, a professional Ainvest editorial member independently reviews, fact-checks, and approves all content for accuracy and compliance with Ainvest Fintech Inc.’s editorial standards. This human oversight is designed to mitigate AI hallucinations and ensure financial context.
Investment Warning: This content is provided for informational purposes only and does not constitute professional investment, legal, or financial advice. Markets involve inherent risks. Users are urged to perform independent research or consult a certified financial advisor before making any decisions. Ainvest Fintech Inc. disclaims all liability for actions taken based on this information. Found an error?Report an Issue
Comments
No comments yet